Impact of prophylactic i.v. magnesium on the efficacy of ibutilide for conversion of atrial fibrillation or flutter

American Journal of Health-System Pharmacy

Volumn 60, Issue 22, 2003, Pages 2308-2312

  Kalus, James S ^a,b   Spencer, Anne P ^c   Tsikouris, James P ^d   Chung, Jenny O ^e   Kenyon, Kenneth W ^c   Ziska, Martin ^d   Kluger, Jeffrey ^f   White, C Michael ^a,f,g  

^a HARTFORD HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d TEXAS TECH UNIVERSITY   (United States)

^e PURDUE PHARMA L P   (United States)

^f MUSC ^*  (United States)

^g UC   (United States)

Author keywords

Atrial fibrillation; Cardiac drugs; Combined therapy; Ibutilide; Magnesium; Minerals

Indexed keywords

DIGOXIN; IBUTILIDE; MAGNESIUM; NIFEDIPINE; POTASSIUM CHANNEL; ANTIARRHYTHMIC AGENT; MAGNESIUM SULFATE; SULFONAMIDE;

ARTICLE; CARDIOVERSION; CLINICAL PHARMACY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INHIBITION; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPOMAGNESEMIA; MAJOR CLINICAL STUDY; MEDICAL RECORD; MULTICENTER STUDY; PRIORITY JOURNAL; PROPHYLAXIS; SINUS RHYTHM; TERTIARY HEALTH CARE; AGED; CHEMOPROPHYLAXIS; COHORT ANALYSIS; DRUG POTENTIATION; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; METHODOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; CHEMOPREVENTION; COHORT STUDIES; DRUG SYNERGISM; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MAGNESIUM SULFATE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 1542539881     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/60.22.2308     Document Type: Article

References (26)

1. Lazzara R. Antiarrhythmic drugs and torsade de pointes. Eur Heart J. 1993; 14 (suppl H):88-92.
2. Coplen SE, Antman EM, Berlin JA et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation. 1990; 82:1106-10.
3. Erratum in Circulation. 1991; 83:714.
4. Zabel M, Hohnloser SH, Behrens S et al. Differential effects of D-sotalol, quinidine, and amiodarone on dispersion of ventricular repolarization in the isolated rabbit heart. J Cardiovasc Electrophysiol. 1997; 8:1239-45.
5. Waldo AL, Camm AJ, deRuyter H et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet. 1996; 348:7-12.
6. Cropp JS, Antal EG, Talbert RL. Ibutilide: a new class III antiarrhythmic agent. Pharmacotherapy. 1997; 17:1-9.
7. Dunn AB, White CM, Reddy P et al. Efficacy and cost analysis of ibutilide. Ann Pharmacother. 2000; 34:1233-7.
8. Cummins RO, Hazinski MF, Baskett PJ et al. Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2000; 102(Suppl I):II-383.
9. Tzivoni D, Banai S, Schuger C et al. Treatment of torsade de pointes with magnesium sulfate. Circulation. 1988; 77: 392-7.
10. White CM, Xie J, Chow MS et al. Prophylactic magnesium to decrease the arrhythmogenic potential of class III antiarrhythmic agents in a rabbit model. Pharmacotherapy. 1999; 19:635-40.
11. Caron MF, Kluger J, Tsikouris JP et al. Effects of intravenous magnesium sulfate on the QT interval in patients receiving ibutilide. Pharmacotherapy. 2003; 23:296-300.
12. Marrouche NF, Tamassoni G, Saliba W et al. Intravenous magnesium sulfate prevents ibutilide associated development of torsades de pointe in patients undergoing cardioversion of atrial arrhythmias. Pacing Clin Electrophysiol. 2002; 24:706. Abstract.
13. Rasmussen HS, Thomsen PE. The electrophysiological effects of intravenous magnesium on human sinus node, atrioventricular node, atrium, and ventricle. Clin Cardiol. 1989; 12:85-90.
14. DiCarlo LA Jr, Morady F, de Buitleir M et al. Effects of magnesium sulfate on cardiac conduction and refractoriness in humans. J Am Coll Cardiol. 1986; 7:1356-62.
15. Moran JL, Gallagher J, Peake SL et al. Parenteral magnesium sulfate versus amiodarone in the therapy of atrial tachyarrhythmias: a prospective, randomized study. Crit Care Med. 1995; 23:1816-24.
16. Chiladakis JA, Stathopoulos C, Davlouros P et al. Intravenous magnesium sulfate versus diltiazem in paroxysmal atrial fibrillation. Int J Cardiol. 2001; 79: 287-91.
17. White RE, Hartzell HC. Magnesium ions in cardiac function. Regulator of ion channels and second messengers. Biochem Pharmacol. 1989; 38:859-67.
18. Brodsky MA, Orlov MC, Capparelli EV et al. Magnesium therapy in new-onset atrial fibrillation. Am J Cardiol. 1994; 73: 1227-9.
19. Erratum in Am J Cardiol. 1994; 74:639.
20. Gullestad L, Birkeland K, Molstad P et al. The effect of magnesium versus verapamil on supraventricular arrhythmias. Clin Cardiol. 1993; 16:429-34.
21. Reinhart RA. Clinical correlates of the molecular and cellular actions of magnesium on the cardiovascular system. Am Heart J. 1991; 121:1513-21.
22. Lee KS, Lee EW. Ionic mechanism of ibutilide in human atrium: evidence for a drug-induced Na+ current through a nifedipine inhibited inward channel. J Pharmacol Exp Ther. 1998; 286:9-22.
23. Wood MA, Gilligan DM, Brown-Mahoney C et al. Clinical and electrophysiologic effects of calcium channel blockers in patients receiving ibutilide. Am Heart J. 2002; 143:176-80.
24. Tieleman RG, De Langen C, Van Gelder IC et al. Verapamil reduces tachycardia-induced electrical remodeling of the atria. Circulation. 1997; 95:1945-53.
25. Daoud EG, Knight BP, Weiss R et al. Effect of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans. Circulation. 1997; 96:1542-50.
26. Goette A, Honeycutt C, Langberg JJ. Electrical remodeling in atrial fibrillation. Time course and mechanisms. Circulation. 1996; 94:2968-74.